The Familial Hypercholesterolemia market report provides current treatment practices, emerging drugs, Familial Hypercholesterolemia market share of the individual therapies, current and forecasted Familial Hypercholesterolemia market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Familial Hypercholesterolemia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2020-2034
Familial Hypercholesterolemia Disease Understanding and Treatment Algorithm
The Familial Hypercholesterolemia market report gives a thorough understanding of the Familial Hypercholesterolemia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Familial Hypercholesterolemia.Treatment
It covers the details of conventional and current medical therapies available in the Familial Hypercholesterolemia market for the treatment of the condition. It also provides Familial Hypercholesterolemia treatment algorithms and guidelines in the United States, Europe, and Japan.Familial Hypercholesterolemia Epidemiology
The Familial Hypercholesterolemia epidemiology division provide insights about historical and current Familial Hypercholesterolemia patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Familial Hypercholesterolemia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.Country Wise-Familial Hypercholesterolemia Epidemiology
The epidemiology segment also provides the Familial Hypercholesterolemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.Familial Hypercholesterolemia Drug Chapters
Drug chapter segment of the Familial Hypercholesterolemia report encloses the detailed analysis of Familial Hypercholesterolemia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Familial Hypercholesterolemia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.Marketed Drugs
The report provides the details of the marketed product available for Familial Hypercholesterolemia treatment.Familial Hypercholesterolemia Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Familial Hypercholesterolemia treatment.Familial Hypercholesterolemia Market Outlook
The Familial Hypercholesterolemia market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Familial Hypercholesterolemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.This segment gives a thorough detail of Familial Hypercholesterolemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, Familial Hypercholesterolemia market in 7MM is expected to change in the study period 2020-2034.
Key Findings
This section includes a glimpse of the Familial Hypercholesterolemia market in 7MM.The United States Market Outlook
This section provides the total Familial Hypercholesterolemia market size and market size by therapies in the United States.EU-5 Countries: Market Outlook
The total Familial Hypercholesterolemia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.Japan Market Outlook
The total Familial Hypercholesterolemia market size and market size by therapies in Japan is also mentioned.Familial Hypercholesterolemia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Familial Hypercholesterolemia market or expected to get launched in the market during the study period 2020-2034. The analysis covers Familial Hypercholesterolemia market uptake by drugs; patient uptake by therapies; and sales of each drug.This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Familial Hypercholesterolemia Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Familial Hypercholesterolemia key players involved in developing targeted therapeutics.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Familial Hypercholesterolemia emerging therapies.Reimbursement Scenario in Familial Hypercholesterolemia
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.KOL- Views
To keep up with current market trends, we take KOLs and SME's opinion working in Familial Hypercholesterolemia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Familial Hypercholesterolemia market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Familial Hypercholesterolemia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.Scope of the Report
- The report covers the descriptive overview of Familial Hypercholesterolemia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Familial Hypercholesterolemia epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Familial Hypercholesterolemia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Familial Hypercholesterolemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Familial Hypercholesterolemia market
Report Highlights
- In the coming years, Familial Hypercholesterolemia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- Companies and academics are working to assess challenges and seek opportunities that could influence Familial Hypercholesterolemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- The major players are involved in developing therapies for Familial Hypercholesterolemia. Launch of emerging therapies will significantly impact the Familial Hypercholesterolemia market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Familial Hypercholesterolemia
- This in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Familial Hypercholesterolemia Report Insights
- Patient Population
- Therapeutic Approaches
- Familial Hypercholesterolemia Pipeline Analysis
- Familial Hypercholesterolemia Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Familial Hypercholesterolemia Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Familial Hypercholesterolemia Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Familial Hypercholesterolemia Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Familial Hypercholesterolemia market share (%) distribution in 2020 and how it would look like in 2034?
- What would be the Familial Hypercholesterolemia total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Familial Hypercholesterolemia market size during the forecast period (2024-2034)?
- At what CAGR, the Familial Hypercholesterolemia market is expected to grow in 7MM during the forecast period (2020-2034)?
- What would be the Familial Hypercholesterolemia market outlook across the 7MM during the forecast period (2020-2034)?
- What would be the Familial Hypercholesterolemia market growth till 2032, and what will be the resultant market Size in the year 2034?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden and unmet needs of the Familial Hypercholesterolemia?
- What is the historical Familial Hypercholesterolemia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Familial Hypercholesterolemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Familial Hypercholesterolemia?
- Out of all 7MM countries, which country would have the highest prevalent population of Familial Hypercholesterolemia during the forecast period (2020-2034)?
- At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Familial Hypercholesterolemia treatment, along with the approved therapy?
- What are the current treatment guidelines for the treatment of Familial Hypercholesterolemia in the USA, Europe, and Japan?
- What are the Familial Hypercholesterolemia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Familial Hypercholesterolemia?
- How many therapies are developed by each company for Familial Hypercholesterolemia treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Familial Hypercholesterolemia treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Familial Hypercholesterolemia therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Familial Hypercholesterolemia and their status?
- What are the key designations that have been granted for the emerging therapies for Familial Hypercholesterolemia?
- What are the global historical and forecasted market of Familial Hypercholesterolemia?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Familial Hypercholesterolemia market
- To understand the future market competition in the Familial Hypercholesterolemia market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Familial Hypercholesterolemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Familial Hypercholesterolemia market
- To understand the future market competition in the Familial Hypercholesterolemia market
Table of Contents
Executive Summary
Country Wise- Familial Hypercholesterolemia (FH) Epidemiology
The epidemiology segment also provides the Familial Hypercholesterolemia (FH) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Familial Hypercholesterolemia (FH) Drug Chapters
The drug chapter segment of the Familial Hypercholesterolemia (FH) report encloses the detailed analysis of Familial Hypercholesterolemia (FH) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Familial Hypercholesterolemia (FH) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Familial Hypercholesterolemia (FH) Marketed Drugs
Praluent (alirocumab): Sanofi/ Regeneron Pharmaceuticals
Alirocumab is marketed by brand name Praluent, which is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. LDLR is the primary receptor that clears circulating LDL, therefore the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-C. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.
Products detail in the report.
Repatha (evolocumab): Amgen
Evolocumab is a human monoclonal immunoglobulin G2 (IgG2) directed against human proprotein convertase subtilisin kexin 9 (PCSK9). Evolocumab has an approximate molecular weight (MW) of 144 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells.
Evolocumab binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.
Products detail in the report.
Nustendi (bempedoic acid / ezetimibe): Esperion Therapeutics
Nustendi is a combination of bempedoic acid and ezetimibe developed by Esperion Therapeutics. Bempedoic acid has been designed as a once-daily, oral therapy that can significantly reduce low-density lipoprotein cholesterol (LDL-C) levels when added to other lipid-lowering therapies in clinical trials of patients with primary hyperlipidemia who need additional LDL-C lowering.
Products detail in the report.
Familial Hypercholesterolemia (FH) Emerging Drugs
Evinacumab (REGN1500): Regeneron Pharmaceuticals
Evinacumab (REGN1500) is being investigated by Regeneron Pharmaceuticals, which is a fully human monoclonal antibody (mAb) to angiopoietin-like protein 3 (ANGPTL3) that acts as an inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL) administered intravenously. It plays a central role in lipoprotein metabolism by binding to ANGPTL3 with high affinity and specificity, and to completely reverse its inhibitory activity on LPL and EL both in vitro and in vivo thereby reducing the serum triglycerides and VLDL-C levels in the patient (Creative Biolabs, n.d.). ANGPTL3 inhibition increases activity of endothelial lipase and, therefore, decreases HDL-C levels.
Products detail in the report.
Inclisiran (ALN-PCSSC): Novartis
Inclisiran by Novartis is a long-acting, synthetic siRNA directed against PCSK9 and it has been shown to significantly decrease hepatic production of PCSK9 and cause a marked reduction in LDL-C levels. Inclisiran is conjugated to triantennary N-acetylgalactosamine carbohydrates administered via subcutaneous injection. These carbohydrates bind to abundant liver-expressed asialoglycoprotein receptors, leading to the uptake of inclisiran specifically into the hepatocytes.
Products detail in the report.
LIB003 + Evolocumab: LIB Therapeutics
LIB003 is a PCSK9 Inhibitor being developed by LIB Therapeutics, which is administered subcutaneously. The PCSK9 protein is an important regulator of circulating LDL‐C levels, through its inhibitory action on recycling of the LDL receptor (LDLR). LDLR on the liver cell surface binds to LDL and the LDLR-LDL complex is then internalized, after which the LDLR is normally recycled back to the cell surface up to 150 times. Secreted PCSK9 binds to the LDLR on the surface of the hepatocyte, leading to the internalization and degradation of the LDLR in the lysosomes, and reducing the number of LDLRs on the cell surface. Inhibition of secreted PCSK9 should therefore increase the number of available LDLRs on the cell surface and increase uptake of LDL‐C into the cell. PCSK9 inhibition thus offers a novel therapeutic mechanism for the lowering of LDL‐C levels.
Products detail in the report.
Gemcabene: NeuroBo Pharmaceuticals
Gemcabene, a small molecule and is the monocalcium salt of a dialkyl ether dicarboxylic acid [6,6′-oxybis (2,2-dimethylhexanoic acid)] in late-stage clinical development, lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP). It inhibits both cholesterol and fatty acid synthesis as determined by the C-acetate incorporation in hepatocytes. In addition to LDL lowering, gemcabene reduces plasma levels of CRP in patients by 53.5% in monotherapy and by 71% in combination with statins, indicating that this compound may have anti-inflammatory properties.
Products detail in the report.
Resmetirom (MGL-3196): Madrigal Pharmaceuticals
Resmetirom (MGL-3196) is a human body, thyroid hormone. Through activation of its beta receptor it plays a central role in controlling lipid metabolism, impacting a range of health parameters from levels of serum cholesterol and triglycerides to the pathological buildup of fat in the liver. MGL-3196 attempts to exploit this pathway for therapeutic purposes in cardio-metabolic and liver diseases have been hampered by the lack of selectivity of older compounds for the thyroid hormone receptor (THR)-β, chemically-related toxicities and undesirable distribution in the body. Madrigal recognized that greater selectivity for thyroid hormone receptor (THR)-β and liver targeting might overcome these challenges and deliver the full therapeutic potential of THR-β agonism. Madrigal believes that MGL-3196 is the first orally administered, small-molecule, liverdirected, truly β-selective THR agonist that has demonstrated the potential for a broad array of therapeutically beneficial effects, improving components of both metabolic syndrome, such as insulin resistance and dyslipidemia, and fatty liver disease, including lipotoxicity and inflammation.
Products detail in the report.
Familial Hypercholesterolemia (FH) Market Outlook
This section of the report includes the dynamics of market scenario for FH in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
FH is the most common autosomal dominant genetic disease. It is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) and a tendency to early-onset atherosclerotic cardiovascular disease. In general, homozygotes manifest the disease at a much earlier age than heterozygotes, and the condition is more severe. It is important to note that if diagnosed, it can be treated with medicines and a healthy lifestyle.
The current market of familial hypercholesterolemia comprises of several treatment options lying in variable classes, such as Statins, Cholesterol absorption inhibitors (Zetia), MTP inhibitors (Juxtapid), APOB antisense inhibitors (Kynamro; mipomersen sodium), PCSK9 inhibitors (Praluent and Repatha), and others (bile-acid-binding resins). In the case of advanced treatment options, Lipoprotein apheresis can also be opted to treat the patients with FH. While in rare and severe cases, patients can also go for liver transplantation.
The pipeline of FH holds potential products by several key players, such as Regeneron Pharmaceuticals (Evinacumab), Novartis (Inclisiran), LIB Therapeutics (LIB003 with Evolocumab), NeuroBo Pharmaceuticals (Gemcabene), Madrigal Pharmaceuticals (Resmetirom), and Arrowhead Pharmaceuticals (ARO-ANG3).
Key Findings
This section includes a glimpse of the Familial Hypercholesterolemia (FH) 7MM market.
- The market size of Familial Hypercholesterolemia (FH) in the seven major markets is 1,069.27 USD Million in 2017.
- The United States accounts for the largest market size of Familial Hypercholesterolemia (FH), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
- Among the EU5 countries, Germany had the highest market size with 84.82 USD Million in 2017. While Spain had the lowest market size of Familial Hypercholesterolemia (FH).
The United States Market Outlook
This section provides the total Familial Hypercholesterolemia (FH) market size and market size by therapies in the United States.
EU-5 Market Outlook
The total aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Familial Hypercholesterolemia (FH) market size and market size by therapies in Japan are provided.
Familial Hypercholesterolemia (FH) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Familial Hypercholesterolemia (FH) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Familial Hypercholesterolemia (FH) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Familial Hypercholesterolemia (FH) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Familial Hypercholesterolemia (FH) emerging therapies.
Competitive Intelligence Analysis
The publisher performs competitive and market Intelligence analysis of the Familial Hypercholesterolemia (FH) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Familial Hypercholesterolemia (FH), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
- Comprehensive insight has been provided into the Familial Hypercholesterolemia (FH) epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Familial Hypercholesterolemia (FH) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of Familial Hypercholesterolemia (FH) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Familial Hypercholesterolemia (FH) market.
Report Highlights
- In the coming years, Familial Hypercholesterolemia (FH) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Familial Hypercholesterolemia (FH) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Report also covers Mutation-specific diagnosed prevalence of FH, including several mutations such as LDL receptor (LDLR) Mutations, Proprotein Convertase Subtilin/Kexin 9 (PCSK9), Apolipoprotein B (Apo B) and Other rare mutations (SREBP2, and STAP1 genes, LDLRAP1 gene).
- Deleveinsight has segregated prevalence of FH on the basis of genetic types, i.e., homozygous familial hypercholesterolemia (HoFH) and heterozygous hypercholesterolemia (HeFH).
- Expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Familial Hypercholesterolemia (FH). Owing to the positive outcomes of the upcoming products during the developmental stage by key players such as Regeneron Pharmaceuticals, Novartis, LIB Therapeutics, NeuroBo Pharmaceuticals, Madrigal Pharmaceuticals and Arrowhead Pharmaceuticals have a potential to create a significant positive shift in the Familial Hypercholesterolemia (FH) Market Size.
- The publisher has also estimated the diagnosed prevalent population of Coronary Heart Disease (CHD) due to FH.
Familial Hypercholesterolemia (FH) Report Insights
- Patient Population
- Therapeutic Approaches
- Familial Hypercholesterolemia (FH) Pipeline Analysis
- Familial Hypercholesterolemia (FH) Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Familial Hypercholesterolemia (FH) Report Key Strengths
- Eleven Years Forecast
- 7MM Coverage
- Familial Hypercholesterolemia (FH) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Familial Hypercholesterolemia (FH) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Familial Hypercholesterolemia (FH) market share (%) distribution in 2017 and how it would look like in 2030?
- What would be the Familial Hypercholesterolemia (FH) total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Familial Hypercholesterolemia (FH) market size during the forecast period (2020-2030)?
- At what CAGR, the Familial Hypercholesterolemia (FH) market is expected to grow at the 7MM level during the forecast period (2020-2030)?
- What would be the Familial Hypercholesterolemia (FH) market outlook across the 7MM during the forecast period (2020-2030)?
- What would be the Familial Hypercholesterolemia (FH) market growth till 2030 and what will be the resultant market size in the year 2030?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden and unmet needs of Familial Hypercholesterolemia (FH)?
- What is the historical Familial Hypercholesterolemia (FH) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of Familial Hypercholesterolemia (FH) at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Familial Hypercholesterolemia (FH)?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Familial Hypercholesterolemia (FH) during the forecast period (2020-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the treatment of Familial Hypercholesterolemia (FH) along with the approved therapy?
- What are the current treatment guidelines for the treatment of Familial Hypercholesterolemia (FH) in the US and Europe?
- What are the Familial Hypercholesterolemia (FH) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Familial Hypercholesterolemia (FH)?
- How many therapies are developed by each company for the treatment of Familial Hypercholesterolemia (FH)?
- How many emerging therapies are in the mid-stage and late stage of development for the treatment of Familial Hypercholesterolemia (FH)?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Familial Hypercholesterolemia (FH) therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Familial Hypercholesterolemia (FH) and their status?
- What are the key designations that have been granted for the emerging therapies for Familial Hypercholesterolemia (FH)?
- What are the 7MM historical and forecasted market of Familial Hypercholesterolemia (FH)?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the Familial Hypercholesterolemia (FH).
- To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Familial Hypercholesterolemia (FH) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for Familial Hypercholesterolemia (FH) market.
- To understand the future market competition in the Familial Hypercholesterolemia (FH) market.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aegerion Pharmaceutical
- Amgen
- Arrowhead Pharmaceuticals
- Esperion Therapeutics
- LIB Therapeutics
- NeuroBo Pharmaceuticals
- Novartis
- Regeneron Pharmaceuticals
- Sanofi/ Regeneron Pharmaceuticals
